Buikema Jan Willem, Van Der Meer Peter, Sluijter Joost P G, Domian Ibrahim J
Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Stem Cells. 2013 Dec;31(12):2587-98. doi: 10.1002/stem.1467.
Advanced heart failure represents a leading public health problem in the developed world. The clinical syndrome results from the loss of viable and/or fully functional myocardial tissue. Designing new approaches to augment the number of functioning human cardiac muscle cells in the failing heart serve as the foundation of modern regenerative cardiovascular medicine. A number of clinical trials have been performed in an attempt to increase the number of functional myocardial cells by the transplantation of a diverse group of stem or progenitor cells. Although there are some encouraging suggestions of a small early therapeutic benefit, to date, no evidence for robust cell or tissue engraftment has been shown, emphasizing the need for new approaches. Clinically meaningful cardiac regeneration requires the identification of the optimum cardiogenic cell types and their assembly into mature myocardial tissue that is functionally and electrically coupled to the native myocardium. We here review recent advances in stem cell biology and tissue engineering and describe how the convergence of these two fields may yield novel approaches for cardiac regeneration.
晚期心力衰竭是发达国家的一个主要公共卫生问题。这种临床综合征是由存活的和/或功能完全正常的心肌组织丧失所致。设计新方法以增加衰竭心脏中具有功能的人类心肌细胞数量是现代再生心血管医学的基础。已经进行了多项临床试验，试图通过移植多种干细胞或祖细胞来增加功能性心肌细胞的数量。尽管有一些令人鼓舞的迹象表明早期有微小的治疗益处，但迄今为止，尚未显示出有力的细胞或组织植入证据，这凸显了新方法的必要性。具有临床意义的心脏再生需要确定最佳的心肌生成细胞类型，并将它们组装成与天然心肌在功能和电方面相耦合的成熟心肌组织。我们在此回顾干细胞生物学和组织工程学的最新进展，并描述这两个领域的融合如何可能产生心脏再生的新方法。
